Open AccessQiShenYiQi pill improves the reparative myocardial fibrosis by regulating autophagy
Author(s) -
Lv Shichao,
Yuan Peng,
Dong Jianping,
Lu Chunmiao,
Li Meng,
Qu Fan,
Zhu Yaping,
Yuan Zhuo,
Zhang Junping
Publication year - 2020
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.15695
Subject(s) - pi3k/akt/mtor pathway , autophagy , myocardial fibrosis , medicine , protein kinase b , fibrosis , cardiomyopathy , inflammation , ejection fraction , cardiology , pharmacology , chemistry , heart failure , signal transduction , microbiology and biotechnology , biology , apoptosis , biochemistry
Abstract QiShenYiQi pill (QSYQ), a traditional Chinese medicine, is well known for improving the myocardial remodelling, but the dose‐effect relationship of its intervention in the reparative myocardial fibrosis is still unclear. We investigated the effect of QSYQ on the reparative myocardial fibrosis in cardiac myosin‐induced rats and explored its mechanism of action by regulating autophagy. The results indicated that QSYQ increased LVEF and LVFS, and decreased the LVEDD, LVESD, HMI, LVMI, myocardial inflammation histology score, and collagen volume fraction in a dose‐dependent manner. In addition, QSYQ declined the number of autophagosomes, down‐regulated the expression of myocardial Beclin‐1 and LC3B, up‐regulated the expression of myocardial p62 and increased the ratios of myocardial p‐PI3K/PI3K, p‐Akt/Akt and p‐mTOR/mTOR. We provided evidence for that QSYQ could inhibit excessive myocardial autophagy by regulating the PI3K/Akt‐mTOR pathway and can be a potential therapeutic approach in treating the cardiovascular diseases such as myocarditis and dilated cardiomyopathy.